Gene · 7874
Papers4,029
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
501 to 520 of 4,029
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT. | Adv Sci (Weinh) | 2023 | 37867237 | PubTator, text mining | PubMed |
| Cellular Assays for Dynamic Quantification of Deubiquitinase Activity and Inhibition. | J Mol Biol | 2023 | 37858708 | PubTator, text mining | PubMed |
| O-GlcNAc has crosstalk with ADP-ribosylation via PARG. | J Biol Chem | 2023 | 37858678 | PubTator, text mining | PubMed |
| A Rare Case of Hao-Fountain Syndrome Mimicking Fragile X Syndrome. | Cureus | 2023 | 37849578 | PubTator, text mining | PubMed |
| Clustering Protein Binding Pockets and Identifying Potential Drug Interactions: A Novel Ligand-Based Featurization Method. | J Chem Inf Model | 2023 | 37847557 | PubTator, text mining | PubMed |
| Artificial intelligence for prediction of biological activities and generation of molecular hits using stereochemical information. | J Comput Aided Mol Des | 2023 | 37847342 | PubTator, text mining | PubMed |
| Derepressing of STAT3 and USP7 contributes to resistance of DLBCL to EZH2 inhibition. | Heliyon | 2023 | 37829803 | PubTator, text mining | PubMed |
| Editorial: Community series in post-translational modifications of proteins in cancer immunity and immunotherapy, volume II. | Front Immunol | 2023 | 37822939 | PubTator, text mining | PubMed |
| Hypoxia-induced SKA3 promoted cholangiocarcinoma progression and chemoresistance by enhancing fatty acid synthesis via the regulation of PAR-dependent HIF-1a deubiquitylation. | J Exp Clin Cancer Res | 2023 | 37821935 | PubTator, text mining | PubMed |
| USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation. | Cell Death Dis | 2023 | 37821462 | PubTator, text mining | PubMed |
| Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL. | J Clin Oncol | 2023 | 37820294 | PubTator, text mining | PubMed |
| [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer]. | Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi | 2023 | 37805766 | PubTator, text mining | PubMed |
| URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers. | Nat Commun | 2023 | 37805657 | PubTator, text mining | PubMed |
| Targeting TRIP13 for overcoming anticancer drug resistance (Review). | Oncol Rep | 2023 | 37800638 | PubTator, text mining | PubMed |
| Cell-specific secretory granule sorting mechanisms: the role of MAGEL2 and retromer in hypothalamic regulated secretion. | Front Cell Dev Biol | 2023 | 37799273 | PubTator, text mining | PubMed |
| Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment. | Expert Opin Ther Targets | 2023 | 37789645 | PubTator, text mining | PubMed |
| PLK1 maintains DNA methylation and cell viability by regulating phosphorylation-dependent UHRF1 protein stability. | Cell Death Discov | 2023 | 37788997 | PubTator, text mining | PubMed |
| USP47 inhibits m6A-dependent c-Myc translation to maintain regulatory T cell metabolic and functional homeostasis. | J Clin Invest | 2023 | 37788092 | PubTator, text mining | PubMed |
| Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. | Mol Cancer | 2023 | 37784082 | PubTator, text mining | PubMed |
| Writers and readers of H3K9me2 form distinct protein networks during the cell cycle that include candidates for H3K9 mimicry. | Biosci Rep | 2023 | 37782747 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7874/papers?page=26